COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND. ICOPH [Internet]. 2025 Jan. 23 [cited 2026 Feb. 4];9(1):45-67. Available from: https://proceedings.tiikmpublishing.com/index.php/icoph/article/view/1543